Dr. Tripathy Discusses HER2 Targeted Therapies

Debu Tripathy, MD
Published: Monday, Aug 22, 2011

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the order that various HER2 targeted therapies should given to breast cancer patients.

Tripathy explains that a hard-set guideline has not been established. He describes that it has become increasingly more likely that a patient will receive trastuzumab (Herceptin) in the adjuvant setting and that because of this HER2/neu positive recurrences usually have already received the drug, warranting a new approach.

The two main choices for patients with HER2 overexpression is trastuzumab with a different chemotherapy or lapatinib (Tykerb) with capecitabine (Xeloda). It has not been established which treatment should be used first. There is evidence to support using either drug. In many cases it is acceptable to use one drug first or to interchange treatments.
Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the order that various HER2 targeted therapies should given to breast cancer patients.

Tripathy explains that a hard-set guideline has not been established. He describes that it has become increasingly more likely that a patient will receive trastuzumab (Herceptin) in the adjuvant setting and that because of this HER2/neu positive recurrences usually have already received the drug, warranting a new approach.

The two main choices for patients with HER2 overexpression is trastuzumab with a different chemotherapy or lapatinib (Tykerb) with capecitabine (Xeloda). It has not been established which treatment should be used first. There is evidence to support using either drug. In many cases it is acceptable to use one drug first or to interchange treatments.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x